Phathom Pharmaceuticals, Inc.
PHAT
$10.48
$0.100.96%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.62% | -26.68% | 13.00% | 6.42% | -10.37% |
| Total Depreciation and Amortization | -2.82% | -8.29% | 1.05% | -3.05% | -7.94% |
| Total Amortization of Deferred Charges | 5.46% | 10.65% | 6.79% | 17.80% | 5.49% |
| Total Other Non-Cash Items | 4.01% | -9.28% | -3.18% | -3.95% | 2.42% |
| Change in Net Operating Assets | 33.24% | 1.35% | -752.42% | 321.25% | 91.08% |
| Cash from Operations | 26.14% | -33.84% | 0.18% | 10.11% | -2.46% |
| Capital Expenditure | -438.89% | -260.00% | 88.64% | 4.35% | -15.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -438.89% | -260.00% | 88.64% | 4.35% | -15.00% |
| Total Debt Issued | -- | -- | -- | -100.00% | 150.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -98.94% | 581,123.81% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -78.66% | 392.74% | 150.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.14% | -127.04% | -164.02% | 227.05% | 22.25% |